Endocrine Abstracts

Aim: To determine the current practice of radioiodine dose treatment provided in Hull and East Yorkshire NHS Trust, in line with the recommended guidelines of the Royal College of Physicians and published data.

Methods: The medical records of the patients who received more than one dose of radioactive iodine for the treatment of thyrotoxicosis in Hull and East Yorkshire NHS Trust between 2006 and 2018 were reviewed retrospectively. The level of the biochemical thyroid function tests including thyroid stimulating hormone, free T4 and free T3 was recorded. The number of how many doses of radioactive iodine treatment was calculated. Each dose of radioactive iodine therapy was noted.

Results: The average range of age in our study is between 28 and 82 with average age at 54.5. The percentage of female gender was 73% while male sex was 28%. During the study period, a total of 33 patients received more than one dose of radioactive iodine. 60% had diagnosis of Grave’s disease, 37% had multinodular goitre and 3% had toxic adenoma. Analysis of biochemical average thyroid function test showed 36.5% had T4, T3 from 1 to 1.5 times above normal level, 54.5% had T4 and T3 from 1.5 to 2 times above normal range and 9% had from 2 to 3 times T4, T3 above normal range. Looking at initial medical treatment, 88% received carbimazole and 12% had propylthiouracil as they were intolerant to carbimazole. The dose of antithyroid medication was variable according to thyroid function test. 100% of patients received a radioactive iodine dose of 400 MBq either in the as a first dose of radioactive iodine or in subsequent doses. 9% of the patients received three times of radioactive iodine treatment and 91% received two times radioactive iodine treatment with optimal responses.